Celtarys

Spain Founded: 2021 • Age: 5 yrs
Company that develops and commercializes novel fluorescent probes and ligands for fluorescence-based methods in drug discovery
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products 4 Services tracked
Competitors 10 Brand Intelligence

About Celtarys

Celtarys is a company based in Spain founded in 2021. Celtarys offers products and services including GPCR Ligands, Adenosine Receptors, Adrenergic Receptors, and CRO Services. Celtarys operates in a competitive market with competitors including AnalytiCon Discovery, Magellan BioScience Group, C2 Pharma, BJ Biochem and Metagreen, among others.

  • Headquarter Spain
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Celtarys Research
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $81.91 K (USD), Grant

    Jul 01, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Celtarys

Celtarys offers a comprehensive portfolio of products and services, including GPCR Ligands, Adenosine Receptors, Adrenergic Receptors, and CRO Services.

Primary

Fluorescent ligands for high-throughput drug screening assays

Specific ligands targeting adenosine receptors in drug discovery

Ligands for adrenergic receptor studies in research applications

Custom development for drug discovery and optimization processes

People of Celtarys

Headcount 1-10
Employee Profiles 6
Employee Profiles
People
Paolo Destito
Principal Scientist
People
Alessandro Scandurra
Director of Business Development
People
Maria Majellaro
Co-founder and Chief Scientific Officer
People
Sabrina Louzán
Controller Financiero

Unlock access to complete

Funding Insights of Celtarys

  • Total Funding
  • Total Rounds 1
  • Last Round Grant — $81,911
  • First Round

    (01 Jul 2023)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2023 Amount Grant - Celtarys Valuation

investors

Investors in Celtarys

Celtarys has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.

All
Institutional
Investor Description Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location

Investments & Acquisitions by Celtarys

Investments

Financial Statements - Celtarys

Celtarys Comparisons

+
Add Comparison
Available on Premium

Competitors of Celtarys

Celtarys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AnalytiCon Discovery, Magellan BioScience Group, C2 Pharma, BJ Biochem and Metagreen, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Natural products chemistry is specialized in by AnalytiCon Discovery.
domain founded_year HQ Location
Identifies and develops microbial natural product leads for pharmaceutical and industrial applications
domain founded_year HQ Location
Manufactures and distributes active pharmaceutical ingredients and compounds worldwide.
domain founded_year HQ Location
Research and development services for sugar derivatives are provided.
domain founded_year HQ Location
Develops technologies to harness compounds from natural production.

Latest news on Celtarys

Frequently Asked Questions about Celtarys

Celtarys was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Celtarys is headquartered in Spain.

Celtarys was founded in 2021 in Spain as a biotech company focused on research. Novel chemical tools are developed and commercialized to support fluorescence-based methods in drug discovery. Fluorescent probes are designed and synthesized for various therapeutic targets, through which drug development processes are streamlined. Operations center on advancing biomedical research tools, with applications in the pharmaceutical sector across Europe.

Celtarys's top competitors include AnalytiCon Discovery, BJ Biochem and Magellan BioScience Group.

Celtarys offers GPCR Ligands, Adenosine Receptors, Adrenergic Receptors, and CRO Services.

Celtarys has 1 investor. Key investors include European Union.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available